|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||88.07 - 88.10|
|52 Week Range||88.07 - 88.10|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Biopharmaceutical company Parexel confirmed Tuesday morning it will be acquired by Pamplona Capital for $88.10 per share in cash, in a transaction valued at approximately $5 billion.
The long-awaited PAREXEL (PRXL) acquisition by Pamplona Capital Management finally receives shareholders' approval. Moreover, the company plans to go private post-acquisition.
The fate of Obamacare will be decided on Sep. 30. No matter what the future holds, the day will provide investors a clear picture of where the MedTech industry is headed.
In view of the current political scenario and banking on favorable metrics, these five MedTech stocks stand out as the most suitable value picks.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to PAREXEL International Corp. Here are 5 ETFs with the largest exposure to PRXL-US. Comparing the performance and risk of PAREXEL International Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
In view of the current political scenario and banking on favorable metrics, these three low-beta MedTech stocks stand out as the most suitable value picks.
On a per-share basis, the Waltham, Massachusetts-based company said it had net income of 58 cents. Earnings, adjusted for one-time gains and costs, came to $1.02 per share. The results surpassed Wall Street ...
We believe tie-ups like these will help PAREXEL (PRXL) drive its top and bottom line. The company also has a competitive edge in the Asia-Pacific markets.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting PRXL. Over the last one-month, outflows of investor capital in ETFs holding PRXL totaled $408 million.
Rating Action: Moody's assigns a B2 CFR to PAREXEL; outlook stable. Global Credit Research- 08 Aug 2017. New York, August 08, 2017-- Moody's Investors Service, assigned a B2 Corporate Family Rating and ...
The Medical sector is likely to benefit from inorganic growth, product launches, technology upgrades. However, regulatory hassles might offset its growth potential.
PAREXEL International Corporation (PRXL) was recently nominated as a CEO Cancer Gold Standard employer by CEO Roundtable on Cancer.
PAREXEL International Corporation (PRXL) recently announced that it has agreed to be acquired by Pamplona Capital Management, LLP.
Stocks that moved substantially or traded heavily Tuesday: Parexel International Corp., up $3.12 to $87.04 The biopharmaceutical services provider said it will go private following a buyout by Pamplona ...